IV Fosfomycin To The Rescue – And To a Place Near You

A recent letter to the Editor by Simkins et al. is worth reviewing [1]. The authors describe the complicated course of a patient who suffered graft rejection after liver transplantation, received broad-spectrum antibiotics during prolonged hospitalization and eventually had a bloodstream infection with carbapenem-resistant Klebsiella pneumoniae (CRKP) which was resistant Continue reading IV Fosfomycin To The Rescue – And To a Place Near You

Brincidofovir – Another Drug Fails in Phase 3

It is sad to see a pivotal trial fail, and you have to wonder why we recently had several such late-stage ‘mishaps’. Take Tetraphase’s eravacycline which failed in a Phase 3 cUTI trial. We have analyzed this drug’s failure in earlier blogs; there is reason to believe that inadequate dosing was Continue reading Brincidofovir – Another Drug Fails in Phase 3

The 10 x ’20 Goal – Are We On Track?

In the last decade (2000-2010), we saw the number of new antibiotic approvals drop successively each year; FDA changed the rules of the approval process without providing public guidance; many antibiotic companies fled the therapeutic area; investments were redirected to oncology projects which had a much better ROI. The IDSA Continue reading The 10 x ’20 Goal – Are We On Track?